News - Page 101 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE

FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE

Post published:July 13, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Post published:July 12, 2022
Post category:Press Release

Read more about the article Psychedelic Research Bulletin: June 2022

Psychedelic Research Bulletin: June 2022

Post published:July 11, 2022
Post category:Psychedelics Research Review

Read more about the article Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics

Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics

Post published:July 11, 2022
Post category:Psychedelic Bulletin

Read more about the article FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

Post published:July 8, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Post published:July 7, 2022
Post category:Press Release

Read more about the article Numinus to Host Q3 2022 Results Conference Call on July 14, 2022

Numinus to Host Q3 2022 Results Conference Call on July 14, 2022

Post published:July 7, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

Post published:July 7, 2022
Post category:Press Release

Read more about the article FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE

FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE

Post published:July 7, 2022
Post category:Press Release

Read more about the article Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders

Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders

Post published:July 7, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.